Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Identification of a novel long-acting 4’-modified nucleoside reverse transcriptase inhibitor against HBV

Journal of Hepatology(2020)10.1016/j.jhep.2020.12.006Source: DataRank Database

Identification of a novel long-acting 4’-modified nucleoside reverse transcriptase inhibitor against HBV is a research paper published in Journal of Hepatology (2020). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.88)OA: hybridTopics (57)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Sanae Hayashi,Hiroki Kumamoto,Hiromi Ogata-Aoki ORCID,Debananda Das ORCID,David Venzon ORCID

Live enrichment

PubMed:33333207 PMC:PMC9703152 OpenAlex:https://openalex.org/W3111010243

Japan Agency for Medical Research and Development

Grant: JP18fk0410001

Japan Agency for Medical Research and Development

Grant: JP16fk0310501

Japan Agency for Medical Research and Development

Grant: JP20fk0310101

Japan Agency for Medical Research and Development

Grant: JP20fk031011 3

Japan Society for the Promotion of Science

Grant: 17K19577

Japan Society for the Promotion of Science

Grant: H04222

Japan Society for the Promotion of Science

Grant: 17H04222

Intramural NIH HHS

Grant: ZIA BC011486

National Cancer Institute

National Institutes of Health

FWCI

2.88

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jhep.2020.12.006

publisherhttps://doi.org/10.1016/j.jhep.2020.12.006

publisherhttps://api.elsevier.com/content/article/PII:S0168827820338435?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0168827820338435?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33333207

Fields of Study

Hepatitis B Virus StudiesPneumocystis jirovecii pneumonia detection and treatmentHepatitis Viruses Studies and EpidemiologyAnimalsDelayed-Action PreparationsDisease Models, AnimalDrug Administration RoutesDrug Administration ScheduleDrug DevelopmentDrug Resistance, ViralHepatitis BHepatitis B virusHumansMiceRNA-Directed DNA PolymeraseReverse Transcriptase InhibitorsTime

MeSH Terms

Drug DevelopmentAnimalsDelayed-Action PreparationsDisease Models, AnimalDrug Administration RoutesDrug Administration ScheduleHepatitis BHepatitis B virusHumansRNA-Directed DNA PolymeraseTimeReverse Transcriptase InhibitorsDrug Resistance, ViralMice

Keywords

Tenofovir alafenamideAdefovirEntecavirReverse transcriptaseViremiaVirologyNucleoside analogueHepatitis B virusIn vitroNucleoside Reverse Transcriptase InhibitorBiologyNucleosideMolecular biologyPharmacologyChemistryVirusRNAViral loadLamivudineBiochemistryAntiretroviral therapyHBVNrtiLong-acting Anti-hbv TherapeuticDrug-resistant HbvsHuman-liver-chimeric Mice

Sustainable Development Goals

SDG 0: Responsible consumption and production